2 Information about ruxolitinib

Marketing authorisation indication

2.1 Ruxolitinib (Jakavi, Novartis Pharmaceuticals) is indicated for 'the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea [hydroxycarbamide]'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics for ruxolitinib.


2.3 The list prices of ruxolitinib for 56‑capsule packs are £1,428 (5 mg), £2,856 (10 mg), £2,856 (15 mg) and £2,856 (20 mg; all prices excluding VAT; BNF online accessed May 2023).

2.4 The company has a commercial arrangement. This makes ruxolitinib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)